 |
|
|
 |
PROCEEDINGS of OMERACT 8
Outcome Measures in Psoriatic Arthritis DAFNA D. GLADMAN, PHILIP J. MEASE, PAUL HEALY, PHILIP S. HELLIWELL, OLIVER FITZGERALD, ALBERTO CAULI, ENNIO LUBRANO, GERALD G. KRUEGER, DÉSIRÉE van der HEIJDE, DOUGLAS J. VEALE, ARTHUR KAVANAUGH, PETER NASH, CHRISTOPHER RITCHLIN, WILLIAM TAYLOR, and VIBEKE STRAND ABSTRACT. Psoriatic arthritis (PsA), an inflammatory arthritis associated with psoriasis usually seronegative for rheumatoid factor, has emerged as a more common and severe disease than previously appreciated. The disease is multifaceted. Thus the assessment of PsA requires attention to peripheral joint involvement, axial disease, dactylitis, and enthesitis, as well as the skin manifestations. In addition, the assessment of patient reported features such as patient assessment of disease activity, pain, fatigue, quality of life, and the new concept of participation are important. The assessment of damage and the assessment of tissue histology are also important outcome measures. This article summarizes these features of PsA as well as current knowledge on the instruments available for the assessment of these domains. (J Rheumatol 2007;34:1159–66) Key Indexing Terms:
PSORIATIC ARTHRITIS From The University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, San Diego; Division of Immunology, Stanford University, Stanford, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Clinical Immunology Research Center, University of Rochester Medical School, Rochester, NY, USA; Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK; St. Vincent's University Hospital, Dublin, Ireland; Rheumatology Unit, Department of Medicine, University of Cagliari, Monserrato; Rheumatology Unit, Fondazione Maugeri, Istituto Scientifico Telese Terme (BN), Italy; Department of Rheumatology, University Hospital Maastricht, and Caphri Research Institute, University Maastricht, Maastricht, The Netherlands; Rheumatology Research Unit, Nambour Hospital, Department of Medicine, University of Queensland, Australia; Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. Partially supported by GRAPPA. Dr. Healy is an OMERACT fellow supported by GRAPPA and the European League Against Rheumatism (EULAR). D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, Director, Psoriatic Arthritis Program University Health Network; P.J. Mease, MD, Seattle Rheumatology Associates, Chief, Swedish Medical Center, Rheumatology Research Division, Clinical Professor, University of Washington School of Medicine; P. Healy, MBChB, FRACP; P.S. Helliwell, MD, PhD, Rheumatology and Rehabilitation Research Unit, University of Leeds; O. FitzGerald, MD, FRCP, FRCPI, Newman Clinical Research Professor, Consultant Rheumatologist, St. Vincent's University Hospital; A. Cauli, MD PhD, Rheumatology Unit, Department of Medicine, University of Cagliari; E. Lubrano, MD, PhD, Consultant Rheumatologist, Rheumatology Unit, Fondazione Maugeri, Istituto Scientifico Telese Terme (BN); G.G. Krueger, MD, Department of Dermatology, University of Utah; D.M.F.M. van der Heijde, MD, PhD, Professor of Rheumatology, Department of Rheumatology, University Hospital Maastricht, and Caphri Research Institute, University Maastricht; D.J. Veale, MD, FRCPI, FRCP(Lon), Consultant Rheumatologist, St. Vincent's University Hospital, and The Conway Institute of Biomolecular and Biomedical Research; A.F. Kavanaugh, MD, Professor of Medicine, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, Senior Lecturer, Department of Medicine, University of Queensland; C.T. Ritchlin, MD, Associate Professor of Medicine, Director, Clinical Immunology Research Center, University of Rochester Medical School; W.J. Taylor, MBChB, FRACP, FAFRM, Senior Lecturer, Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago; C.V. Strand, MD, Clinical Associate Professor, Division of Immunology, Stanford University. Address reprint requests to Dr. D.D. Gladman, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 1E-410B, 399 Bathurst St., Toronto, Ontario M5T 2S8, Canada. E-mail: dafna.gladman@utoronto.ca
|
